0001601485 false 06/17/2026 Nasdaq☒0001601485 2026-06-17 2026-06-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 17, 2026
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware | 001-39990 | 11-3430072
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.)
| 451 D Street, 5th Floor |
| Boston, Massachusetts 02210 |
| (Address of principal executive offices, including zip code) |

(857) 209-0050
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

(Title of each class) | (Trading Symbol) | (Name of exchange on which registered)
Common Stock, $0.01 par value per share | ELTX | The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.
On June 17, 2026, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition as well as the Company’s plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, subject to funding. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

Exhibit Number |  | Exhibit Description
99.1 |  | Press Release dated June 17, 2026.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | Elicio Therapeutics, Inc.
|  |  | By: |  | /s/ ROBERT CONNELLY
Date: June 17, 2026 |  |  |  |  | Robert Connelly President and Chief Executive Officer (Principal Executive Officer)